Lupin Q1 FY27 Results: Key numbers to watch on Aug 6

Results on August 6, earnings call on August 7

Lupin Ltd (NSE: LUPIN) is set to consider its Q1 FY27 financial results for the quarter ended June 30, 2026. The company’s board is scheduled to meet on Thursday, August 6, 2026, to review and approve the numbers. While the exact release time for the results has not been officially specified in advance, the disclosure is expected during or after the board meeting and then filed with the BSE and NSE.

The company has also scheduled an earnings conference call for Friday, August 7, 2026 at 4:30 PM IST. The call, announced in a regulatory communication dated July 22, 2026, is expected to cover Q1 performance and management commentary on the outlook.

Key calendar items investors are tracking

Besides the quarterly results and call, Lupin’s broader calendar includes corporate actions and compliance timelines referenced in the supplied material. The trading window is stated to be closed from July 1 until August 9, 2026. Lupin’s forty-fourth Annual General Meeting (AGM) is scheduled for August 4, 2026, to seek shareholder approval for a final dividend of ₹18 per equity share.

Taken together, these dates matter because they shape information flow for the stock through early August. With no pre-announced result release time, investor attention typically shifts to exchange filings and subsequent management commentary.

Revenue expectations: wide range, tough base

Expectations provided for Lupin’s Q1 FY27 results point to consolidated revenue in a broad range of approximately ₹6,300 crore to ₹7,096 crore. For comparison, Q1 FY26 revenue is referenced at ₹6,268.34 crore in one part of the supplied material. Another section notes Lupin’s official Q1 FY26 release reported sales of ₹6,163.8 crore, highlighting that “sales” and “revenue from operations” can differ based on definition.

Some supplementary material also cites an “analyst consensus” revenue estimate of ₹6,632 crore. This sits within the broader expectation band cited elsewhere.

PAT estimates: mixed signals across sources

On profitability, one set of estimates in the provided content places Q1 FY27 profit after tax (PAT) in the range of roughly ₹927 crore to ₹1,179 crore. That compares with Q1 FY26 PAT of about ₹1,221.5 crore (also referenced as ₹1,219.03 crore in another passage).

Separately, the supplied video transcript text includes a net profit/PAT figure of ₹153 crore. The material does not explain the basis for that number (for example, whether it refers to a different profit line, a different scope, or a different estimate set). Given the wide divergence, investors are likely to rely on Lupin’s reported results and reconciliation details.

EBITDA margin focus: guidance points to 24-25%

Margin trajectory is a key focus in the supplied material. Expectations cited for Q1 FY27 EBITDA margin are around 24% to 25%, versus 29.3% in Q1 FY26 (as per the table provided). Another section highlights that Q4 FY26 EBITDA margin was 29.4%, and that margins are expected to moderate toward the guided 24% to 25% band for FY27.

The video transcript also mentions a prior-quarter peak EBITDA margin of 33% in Q4 FY26, followed by an expected drop to 24% to 25%. The same transcript attributes this to a high base effect and “one-off settlements” in the previous quarter.

R&D intensity remains a tracked line item

The supplied expectations table places R&D as a percentage of sales at 7.5% to 8.5% for Q1 FY27, compared with 7.9% in Q1 FY26. Separately, the broader FY27 targets mentioned include R&D spend of around 8% of sales.

R&D intensity matters for Lupin because it links directly to product pipeline execution, filings, and longer-term competitiveness. For near-term results, the market typically tracks whether R&D spends stay within stated bands and how that interacts with operating margin.

US business: pricing, competition, and run-rate targets

The US generics business is repeatedly highlighted as a pressure point and a swing factor. Management guidance cited in the material points to high single-digit to low double-digit USD erosion in the US segment for FY27, driven by increased competition in certain products such as Tolvaptan.

At the same time, the supplied notes indicate a target to maintain a greater than USD 1 billion revenue run-rate in the US business for FY27. Another reference pegs FY26 US revenue at USD 1.3 billion, with expectations of erosion versus that level.

India and emerging markets: domestic growth versus global headwinds

The India prescription business is described as a support pillar, with the supplied material noting it has historically tracked ahead of the broader market’s roughly 13.5% year-on-year growth. The material also states that the India prescription business plans 20 product launches in FY27.

Emerging markets are described as maintaining strong momentum, with 35.2% year-on-year growth “last year” cited in the content and specific mention of Brazil and South Africa as key contributors. These details frame how investors may interpret consolidated growth mix when results are released.

One-offs, settlements, and balance sheet context

The supplied content notes that the upcoming call may clarify the “clean profit trajectory” now that exceptional items from the previous fiscal year have been accounted for. A specific example cited is a Mirabegron settlement of ₹847.55 crore.

On the balance sheet, the material states Lupin’s net cash position improved to ₹4,636 crore as of March 31, 2026, up from ₹310 crore a year ago. The same notes add that there are no direct references to fundraising through debt or equity in the provided pages.

Market snapshot and recent reported quarter

The supplied snapshot lists Lupin’s market cap at ₹110,421.66 crore and a current market price (CMP) of ₹2,415.0 in one section, while another line shows price at ₹2,368 and market cap around ₹1.0 lakh crore. A separate passage notes the stock around ₹2,397.5 on NSE as of July 2026. These figures reflect different capture points in the material, rather than a single official reference.

Operationally, Q4 FY26 revenue from operations is stated at ₹7,391.9 crore, with Q4 FY26 PAT at ₹1,460.4 crore and EBITDA margin at 29.4%. That quarter is also described as a strong base, which matters when interpreting year-on-year comparisons.

Key numbers and events at a glance

What to listen for on the August 7 management call

With US pricing pressure and margin normalisation a recurring theme in the provided material, commentary on US demand, competitive intensity, and product-level developments is likely to be closely parsed. Investors will also track how Lupin frames its FY27 goals mentioned in the notes: high single-digit revenue growth, EBITDA margin around 25%, maintaining a greater than USD 1 billion US run-rate, and R&D around 8% of sales.

The results and call may also help reconcile the differing profit estimates present in the supplied material, especially given the gap between the ₹927-₹1,179 crore PAT band and the ₹153 crore figure cited in a transcript excerpt.

Conclusion

Lupin’s Q1 FY27 results, scheduled for board review on August 6, 2026, arrive with revenue expectations ranging from ₹6,300 crore to ₹7,096 crore and EBITDA margin estimates around 24% to 25%. The August 7 earnings call at 4:30 PM IST is the next key checkpoint for details on the US generics environment, margin drivers, and how management positions its FY27 targets. Investors will also watch for clarity on one-off impacts referenced in the material and how the quarter compares with the strong base highlighted in prior periods.